Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
NEOVACS logo — Nous développons les thérapies de demain et investissons dan...

NEOVACS

Nous développons les thérapies de demain et investissons dans des sociétés innovantes en Biotech et Medtech

Founded 1993 France France 18 employees Post Ipo Equity Total: $37.95M Biotechnology, Health Care +2

General Information

Company Name NEOVACS
Founded Year 1993
Location France France +1
Employees 18
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Post Ipo Equity
Social

Get notified when NEOVACS moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About NEOVACS

**NEOVACS**

NEOVACS is a French Biotechnology company founded in 1993. Their mission is to develop therapeutic vaccines for the treatment of autoimmune and inflammatory diseases. Additionally, they invest in innovative companies within the Biotech and Medtech industries. Their headquarters are based in France.

The most recent investment in NEOVACS was a €1.20M post-IPO equity investment on 05 May 2025. The details of the investing party are not stated.

NEOVACS presents an interesting prospect for venture capitalists looking to invest in the biotech and medtech sectors. With a strong focus on therapeutic vaccines and a track record of investment in innovative companies, they are positioned as a promising player in the health and wellness industry.

Taxonomy: Therapeutic Vaccines, Autoimmune Diseases, Inflammatory Diseases, Immunotherapy, Medtech, AIDS Treatment, Cancer Treatment, Polyclonal Antibody Response, Immunologist, Viral Proteins, Monoclonal Antibodies, Cytokine-related Diseases, Allergic Diseases

Services & Products

biotechnology research and development
drug development
investing in biotech and medtech companies

Target Customers

patients with lupus and allergies biotech and medtech companies

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 05 May 2025
Post-IPO Equity •••••• - 22 Jan 2025
Post-IPO Debt •••••• - 22 Jun 2021
Post-IPO Debt •••••• 1
Investor
08 Feb 2021
Post-IPO Equity •••••• - 31 Jul 2017

View All 9 Funding Rounds

NEOVACS Alternatives & Competitors

NEOVACS vs
ZaBeCor Pharmaceuticals
ZaBeCor Pharmaceuticals

Pioneering molecular advancements for asthma, allergies, and a spectrum of inflammatory and infectio...

Series Unknown
2 employees
Biotechnology, Health Care
NEOVACS vs
INGENIA Therapeutics
INGENIA Therapeutics United States

INGENIA Therapeutics strives to develop antibodies to treat multiple diseases including cancer & inf...

14 employees
NEOVACS vs
Biosun Pharma
Biosun Pharma

Pioneering advancements in the treatment of tumors, self-immune, and inflammatory diseases for a hea...

Series B
Biopharma, Pharmaceutical

FAQ About NEOVACS

Nous développons les thérapies de demain et investissons dans des sociétés innovantes en Biotech et Medtech
NEOVACS was founded in 1993.
NEOVACS is headquartered in France.
NEOVACS operates in the following industries: Biotechnology, Health Care, Health and Wellness, Medical Devices.
NEOVACS has approximately 18 employees.
NEOVACS has completed 9 funding rounds, raising a total of $37.95M. The latest funding stage is Post Ipo Equity.
NEOVACS offers: biotechnology research and development, drug development, investing in biotech and medtech companies.
Top alternatives and competitors to NEOVACS include ZaBeCor Pharmaceuticals, INGENIA Therapeutics, Biosun Pharma, Lorantis, RudaCure. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NEOVACS and ZaBeCor Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors NEOVACS and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy